Sanofi-Aventis, the manufacturer of Taxotere, is accused of failing to warn patients undergoing chemotherapy about the risk of permanent hair loss.

Before the FDA updated the label for the drug in December 2015, the label on Taxotere reassured patients that “hair generally grows back” after completing treatment. However, the drug-maker’s own studies estimated that 9% of patients experienced persistent or permanent hair loss.


If you or a loved one has suffered permanent hair loss after taking the drug Taxotere, contact us today for a free consultation.  Allan Berger & Associates is accepting cases in the New Orleans area and nationwide.